Branded medicines sales clawback cap

STO-REC-STATGMYPTHT2 National
15%

United Kingdom · as of 8 Sep 2026

Branded medicines sales clawback cap in United Kingdom stood at 15% as of 8 September 2026 (ABPI).

Original source
Publisher
ABPI
Authority tier
T2 National
Locator
UK competitive weaknesses
Retrieved
17 Sep 2026
Status
Verified

What the source says

Despite a new 15 per cent cap on branded medicines sales clawback rates, the UK's rate on newer medicines remains higher than every other comparator country in the analysis, several of which operate no clawback system at all.

Verbatim extraction verified: The figure 15% is directly attested in the quoted passage (UK competitive weaknesses).

The figure above was extracted from this passage. If it does not match, the extraction is wrong and we want to know.

Cite this figure

Published under CC BY 4.0. Attribute the original publisher; the citations below do that for you and link to this permanent record.

APA
Association of the British Pharmaceutical Industry. (2026). Green shoots for UK pharma investment, but delivery will decide whether they take root. Retrieved September 17, 2026, from https://www.abpi.org.uk/media/news/2026/august/green-shoots-for-uk-pharma-investment-but-delivery-will-decide-whether-they-take-root/. Via StatOrigin, https://statorigin.org/stat/stat_GMYPTHCR25PSS2A2G385G7T53M
MLA
Association of the British Pharmaceutical Industry. "Green shoots for UK pharma investment, but delivery will decide whether they take root." 2026, https://www.abpi.org.uk/media/news/2026/august/green-shoots-for-uk-pharma-investment-but-delivery-will-decide-whether-they-take-root/. Accessed 17 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_GMYPTHCR25PSS2A2G385G7T53M.
Chicago
Association of the British Pharmaceutical Industry. "Green shoots for UK pharma investment, but delivery will decide whether they take root." 2026. https://www.abpi.org.uk/media/news/2026/august/green-shoots-for-uk-pharma-investment-but-delivery-will-decide-whether-they-take-root/. Accessed September 17, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_GMYPTHCR25PSS2A2G385G7T53M.
BibTeX
@misc{abpi2026brandedg7t53m, author = {{Association of the British Pharmaceutical Industry}}, title = {Green shoots for UK pharma investment, but delivery will decide whether they take root}, year = {2026}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_GMYPTHCR25PSS2A2G385G7T53M}, note = {Original source: https://www.abpi.org.uk/media/news/2026/august/green-shoots-for-uk-pharma-investment-but-delivery-will-decide-whether-they-take-root/. Accessed September 17, 2026.} }

Provenance and verification

Everything needed to check this number yourself, without taking our word for it.

Chain of Custody · Verification Audit
Record: STO-REC-STATGMYPTH T2 National

Primary Source

Publisher
Association of the British Pharmaceutical Industry · homepage ↗
Authority tier
Tier 2 · National Official
Report
Green shoots for UK pharma investment, but delivery will decide whether they take root
Type
Press release
Published
Locator
UK competitive weaknesses
Retrieved
17 September 2026
Link status
Reachable (HTTP 200)
Report licence
See source

Verification & Integrity

Audit status
Verified
Review protocol
Editorial review
Checked on
17 September 2026
Last revision
17 September 2026
Archival URI
/stat/stat_GMYPTHCR25PSS2A2G385G7T53M